Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Correction: Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach.
Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS.
Erratum to: Reassessing the risk of natalizumab-associated PML.
Multiple sclerosis: potential risk factors in childhood and adolescence.
How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis.
Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis.
The Role of Astrocytes in Multiple Sclerosis Progression.
Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
A Long Term Analysis of The Clinical And Cost Effectiveness of Glatiramer Acetate From The Uk Multiple Sclerosis Risk Sharing Scheme.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.
Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy.
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
Activation of endogenous neural stem cells for multiple sclerosis therapy.
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.
Multiple sclerosis drugs: Sticker shock.
Distinct T cell signatures define subsets of patients with multiple sclerosis.
Elevation of 20-carbon long chain bases due to a mutation in serine palmitoyltransferase small subunit b results in neurodegeneration.
Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.
CTLA-4 +49 A/G and -318 C/T polymorphisms and susceptibility to multiple sclerosis: a meta-analysis.
Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination.
Fecundity in women with multiple sclerosis: an observational mono-centric study.
Pages
« first
‹ previous
…
695
696
697
698
699
700
701
702
703
…
next ›
last »